Federal Hemp Law in 2026: What Changes on November 12

Public Law 119-37 is already enacted. Its revised federal definition of hemp is scheduled to take effect on November 12, 2026—one year after enactment. Until then, the 2018 federal definition remains the baseline for whether cannabis material falls within the federal hemp exception, while FDA rules, state laws, and other requirements continue to apply.

Several bills would repeal, delay, or build a different regulatory framework around the 2026 change. As of July 12, 2026, those bills remain introduced proposals. They have not displaced the enacted November 12 effective date.

This distinction matters because three different statements are circulating at once:

• Congress enacted a new definition in November 2025.
• The new definition is not yet effective.
• Congress could still amend or repeal it before November 12, 2026.

All three can be true at the same time.

The current federal definition remains in place through November 11

The Agriculture Improvement Act of 2018 defined hemp as Cannabis sativa L. and its parts, derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers with a delta-9 THC concentration no greater than 0.3% on a dry-weight basis.

That definition removed qualifying hemp from the federal Controlled Substances Act definition of marijuana. It did not erase FDA authority, state product rules, or other legal requirements.

Section 781 of Public Law 119-37 says its amendments become effective 365 days after enactment. The law was approved on November 12, 2025, placing the scheduled effective date on November 12, 2026.

An official federal rulemaking document has described the transition this way: products meeting the current 2018 definition remain outside federal controlled-substance treatment as hemp through November 11, 2026, subject to other applicable laws. Beginning November 12, the amended definition controls which products continue to qualify as hemp under the enacted federal text.

What the November 12 definition changes

The new language does more than replace one THC number with another. It changes the measurement named in the plant definition, creates an “industrial hemp” category, defines hemp-derived cannabinoid products, and lists products excluded from “hemp.”

The plant threshold changes to total tetrahydrocannabinols

The amended general definition uses a concentration of no more than 0.3% total tetrahydrocannabinols, including tetrahydrocannabinolic acid, on a dry-weight basis.

That differs from the 2018 language, which names delta-9 THC. The new text expressly includes THCA when describing the total-tetrahydrocannabinols threshold.

Laboratory reports may display delta-9 THC, THCA, and calculated total THC separately. The guide to reading a hemp certificate of analysis explains how to check the analytes, formula, units, dates, and sample identity before drawing a conclusion from those values.

The law expressly includes “industrial hemp”

The amended text says hemp includes industrial hemp, then defines that term around specified non-cannabinoid stalk and seed uses, certain immature-leaf products, research material that does not enter commerce, and viable seed produced for the listed purposes.

That is one reason “all hemp is banned” is not an accurate description of the enacted text. The law preserves a defined industrial-hemp category while changing how cannabinoid products and other material are treated.

Intermediate cannabinoid products receive their own rules

The law defines an intermediate hemp-derived cannabinoid product as material not yet in its final marketed form, or a powder, liquid, tablet, oil, or other form intended to be mixed, dissolved, formulated, or added to another substance before use.

The exclusions cover intermediate products containing:

• cannabinoids that cannot be naturally produced by Cannabis sativa L.;
• cannabinoids capable of occurring in the plant but synthesized or manufactured outside it; or
• more than 0.3% combined total of total tetrahydrocannabinols, including THCA, and other cannabinoids determined by the Secretary of Health and Human Services to have similar effects or to be marketed as having similar effects.

The law also excludes intermediate products marketed or sold as final products or directly to an end consumer for personal or household use.

Final cannabinoid products receive a per-container threshold

For final hemp-derived cannabinoid products, the enacted exclusion includes products containing more than 0.4 milligrams combined total per container of:

• total tetrahydrocannabinols, including THCA; and
• other naturally produced cannabinoids determined by HHS to have similar effects, or marketed as having similar effects, as tetrahydrocannabinols.

The statute defines “container” as the innermost wrapping, package, or vessel in direct contact with the final product for retail sale, such as a jar, bottle, bag, box, packet, can, carton, or cartridge. It excludes bulk shipping containers and nonessential outer wrapping.

The threshold is expressed per container, not simply as a percentage. Applying it to a specific product requires verified composition, units, package structure, and any relevant agency determinations. A product name or category alone is not enough.

What happens to products excluded from “hemp”

The Controlled Substances Act excludes hemp—using the definition in 7 U.S.C. 1639o—from its definition of marijuana. When the revised definition takes effect, material excluded from “hemp” no longer receives that hemp exception merely because it came from a hemp supply chain.

That does not make every legal question identical. Product composition, drug approvals, statutory exclusions, agency rules, state law, litigation, and enforcement posture can affect the analysis. The careful statement is that products outside the amended hemp definition face federal controlled-substance consequences under the broader legal framework; it is not responsible to decide the status of a particular product without its facts.

The law required FDA lists and container guidance

Section 781 directed FDA, in consultation with other federal agencies, to publish within 90 days of enactment:

• cannabinoids known to be capable of natural production by Cannabis sativa L.;
• naturally occurring tetrahydrocannabinol-class cannabinoids;
• other known cannabinoids with similar effects, or marketed as having similar effects; and
• added information about the statutory meaning of “container.”

Those agency materials matter because the amended exclusions refer to what can be naturally produced and to HHS determinations about similar effects. Any product-level review should use the current official agency publication rather than a private list or a seller’s characterization.

Three pending bills would take different approaches

Introduced bills show what members of Congress want to change. They do not change the law unless they pass both chambers and are signed, or otherwise become law under the Constitution.

Measure	Introduced	Verified status on July 12, 2026	Proposed change
H.R. 6209, American Hemp Protection Act of 2025	Nov. 20, 2025	Introduced; referred to House Agriculture	Repeal section 781
H.R. 7010	Jan. 12, 2026	Introduced; referred to House Agriculture	Replace the 365-day delay with a three-year delay
H.R. 7212, Hemp Enforcement, Modernization, and Protection Act	Jan. 22, 2026	Introduced; referred to House Energy and Commerce	Create a federal Food, Drug, and Cosmetic Act framework for cannabinoid hemp products

H.R. 6209 and H.R. 7010 address the section 781 timetable or existence. H.R. 7212 proposes a broader regulatory pathway covering cannabinoid hemp products. None of the three had advanced beyond introduction and committee referral on the verification date.

If one of these measures advances, the relevant questions will be the exact amended text, chamber action, whether the other chamber agrees, the President’s action, and the new effective date. A press release, cosponsor announcement, or committee discussion does not substitute for those steps.

The December 2025 executive order is direction, not a statutory rewrite

A December 18, 2025 executive order directed federal work on marijuana and CBD research and called for collaboration with Congress on the definition and regulation of final hemp-derived cannabinoid products.

The order is important evidence of executive-branch policy. It did not itself repeal section 781, move the effective date, or enact a new cannabinoid-product pathway. Those changes require the relevant legal process.

FDA law remains a separate layer

Federal hemp status under the Agricultural Marketing Act and Controlled Substances Act is not the same as permission to market a food, dietary supplement, drug, cosmetic, or animal product.

The 2018 Farm Bill preserved FDA authority. FDA’s current public guidance says products containing cannabis-derived compounds remain subject to the Federal Food, Drug, and Cosmetic Act and other laws even when the material meets the federal hemp definition.

FDA has also maintained that CBD and THC products cannot presently be marketed as dietary supplements under its interpretation of the drug-exclusion provisions, and that adding CBD or THC to food introduced into interstate commerce is prohibited under the circumstances described in its guidance. FDA has called for a new regulatory pathway rather than treating hemp status as the end of the inquiry.

State law can be more restrictive or simply different

States regulate cultivation, product definitions, potency, age limits, licensing, testing, packaging, marketing, taxes, and sales channels in different ways. A product’s federal hemp classification does not override a state restriction.

State rules also change on their own schedules. Any availability decision needs a current jurisdiction-specific review, including enacted text, effective dates, regulations, agency guidance, and court orders.

What businesses and readers should watch next

Five developments could materially change this account before November 12:

1. Movement on repeal, delay, or regulatory-pathway legislation.
2. New FDA or HHS publications required or contemplated by section 781.
3. Federal regulations or enforcement guidance addressing implementation.
4. Litigation seeking to interpret or block part of the new framework.
5. New state laws or rules that take effect before the federal transition.

The date at the top of an article is not enough for a subject moving this quickly. Check the last-reviewed date and the linked official records.

Current bottom line

As verified on July 12, 2026:

• The revised federal hemp definition is enacted.
• It is scheduled to become effective November 12, 2026.
• The 2018 definition remains the federal baseline through November 11, subject to FDA, state, and other law.
• The enacted change uses total tetrahydrocannabinols, expressly includes THCA, creates industrial-hemp and cannabinoid-product definitions, and imposes new exclusions.
• Bills to repeal, delay, or create a different product framework remain proposals, not law.
• A specific product’s status cannot be determined responsibly from its category name alone.

Related reading

• Total THC and THCA: How the Calculation Works—and Where It Does Not
• How to Read a Hemp Bill Without Mistaking It for Law

See Editorial Standards, Sources, and Corrections for IHF's source, date, claims-boundary, and corrections practices.

Primary sources

• Public Law 119-37
• H.R. 6209 actions
• H.R. 7010 actions and text
• H.R. 7212 actions
• FDA regulation of cannabis and cannabis-derived products
• December 18, 2025 executive order
• Congressional Research Service: Changes to the Statutory Definition of Hemp

Event date: Public Law 119-37 approved November 12, 2025
Scheduled effective date: November 12, 2026
Published: July 12, 2026
Last fact-checked: July 13, 2026
Next review: Weekly through November 20, 2026, and immediately after any relevant federal action.